| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
|
Clin Pharmacol Ther
|
2007
|
2.53
|
|
2
|
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
|
Clin Pharmacol Ther
|
2008
|
1.38
|
|
3
|
Improved separation of chromosome-sized DNA from Trypanosoma brucei, stock 427-60.
|
Nucleic Acids Res
|
1989
|
1.35
|
|
4
|
Molecular cloning of complementary DNAs encoding the heavy chain of the human 4F2 cell-surface antigen: a type II membrane glycoprotein involved in normal and neoplastic cell growth.
|
Proc Natl Acad Sci U S A
|
1987
|
1.35
|
|
5
|
Structure, expression and regulation of the murine 4F2 heavy chain.
|
Nucleic Acids Res
|
1989
|
1.23
|
|
6
|
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
|
Clin Pharmacol Ther
|
2002
|
1.12
|
|
7
|
A detailed mutational analysis of the VSG gene expression site promoter.
|
Mol Biochem Parasitol
|
1996
|
1.07
|
|
8
|
Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
|
J Clin Pharmacol
|
2008
|
1.02
|
|
9
|
Trypanosoma brucei brucei: characterization of an ODC null bloodstream form mutant and the action of alpha-difluoromethylornithine.
|
Exp Parasitol
|
1998
|
0.96
|
|
10
|
Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
|
J Clin Pharmacol
|
2001
|
0.92
|
|
11
|
Binding of trans-acting factors to the double-stranded variant surface glycoprotein (VSG) expression site promoter of Trypanosoma brucei.
|
Mol Biochem Parasitol
|
1997
|
0.88
|
|
12
|
Procyclic Trypanosoma brucei cell lines deficient in ornithine decarboxylase activity.
|
Mol Biochem Parasitol
|
1996
|
0.85
|
|
13
|
Cloning by functional complementation in Trypanosoma brucei.
|
Mol Biochem Parasitol
|
1997
|
0.84
|
|
14
|
The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers.
|
Eur J Clin Pharmacol
|
2007
|
0.83
|
|
15
|
An efficient method for stable transfection of bloodstream-form Trypanosoma brucei.
|
Nucleic Acids Res
|
1996
|
0.80
|
|
16
|
Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.
|
J Clin Pharmacol
|
2005
|
0.79
|
|
17
|
A Trypanosoma brucei bloodstream form mutant deficient in ornithine decarboxylase can protect against wild-type infection in mice.
|
Exp Parasitol
|
1999
|
0.77
|
|
18
|
Analysis of a hybrid PARP/VSG ES promoter in procyclic trypanosomes.
|
Mol Biochem Parasitol
|
1996
|
0.77
|
|
19
|
The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.
|
J Psychopharmacol
|
2011
|
0.77
|
|
20
|
T-cell receptor gene rearrangement and expression in human natural killer cells: natural killer activity is not dependent on the rearrangement and expression of T-cell receptor alpha, beta, or gamma genes.
|
Immunogenetics
|
1988
|
0.75
|
|
21
|
Protozoan genomes : karyotype analysis, chromosome structure, and chromosome specific libraries.
|
Methods Mol Biol
|
1992
|
0.75
|